{"entity":{"id":"epoetin-theta","kind":"drug","name":"Epoetin theta","aka":["epoetin theta","Eporatio","Biopoin"],"tldr":"Epoetin theta is a made-to-order version of erythropoietin, the hormone that tells the marrow to make red blood cells. It is used to treat the anaemia of chemotherapy in people with non-myeloid cancers, sparing some transfusions.","summary":"Epoetin theta is authorised in the EU under two names: Biopoin (authorised 23 October 2009; marketing authorisation holder Teva GmbH) and Eporatio (authorised 29 October 2009; marketing authorisation holder Ratiopharm GmbH, a Teva company per Wikidata Q265318). Both are indicated for symptomatic anaemia associated with chronic renal failure in adults and for symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. The corpus's other erythropoiesis-stimulating agents are epoetin alfa and darbepoetin alfa.","status":"approved","asOf":"2026-09-22","links":[{"label":"EMA: Eporatio (EPAR)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/eporatio"},{"label":"EMA: Biopoin (EPAR)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/biopoin"}],"tags":["ema-register","supportive"],"related":["epoetin-alfa","darbepoetin-alfa"],"cancers":[],"sections":[],"technologies":["transfusion-support"],"targets":["epor"],"drugs":[],"companies":["teva"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (EMA medicines register and EPAR pages)","editedOn":"2026-09-22"},"brand":"Eporatio / Biopoin","modality":"Recombinant erythropoietin (erythropoiesis-stimulating agent)","mechanism":"Recombinant human erythropoietin that acts on the erythropoietin receptor to stimulate red-cell production; used for symptomatic anaemia in adults with non-myeloid cancers receiving chemotherapy and in chronic renal failure (indication wording, EMA).","approvals":[{"region":"EU","year":2009,"indication":"Symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy; anaemia of chronic renal failure","note":"Biopoin authorised 23 Oct 2009 (Teva); Eporatio 29 Oct 2009 (Ratiopharm)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/epoetin-theta/","neighbours":{"drug":[{"id":"darbepoetin-alfa","kind":"drug","name":"Darbepoetin alfa","route":"/drugs/darbepoetin-alfa/"},{"id":"epoetin-alfa","kind":"drug","name":"Epoetin alfa","route":"/drugs/epoetin-alfa/"}],"technology":[{"id":"transfusion-support","kind":"technology","name":"Transfusion support and anaemia management","route":"/technologies/transfusion-support/"}],"target":[{"id":"epor","kind":"target","name":"Erythropoietin receptor (EPOR)","route":"/targets/epor/"}],"company":[{"id":"teva","kind":"company","name":"Teva Pharmaceuticals","route":"/companies/teva/"}]}}